<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04514198</url>
  </required_header>
  <id_info>
    <org_study_id>POP001</org_study_id>
    <nct_id>NCT04514198</nct_id>
  </id_info>
  <brief_title>Postoperative Pancreatitis and Its Correlation With Clinically Relevant Pancreatic Fistula in Pancreaticoduodenectomy</brief_title>
  <official_title>Postoperative Pancreatitis and Its Correlation With Clinically Relevant Pancreatic Fistula in Pancreaticoduodenectomy- A Prospective Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asian Institute of Gastroenterology, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asian Institute of Gastroenterology, India</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      AIM&#xD;
&#xD;
      To determine association between postoperative pancreatitis and pancreatic fistula&#xD;
&#xD;
      OBJECTIVES&#xD;
&#xD;
        1. To determine incidence of Clinically relevant pancreatic fistula (grade B/C) after&#xD;
           pancreaticoduodenectomy&#xD;
&#xD;
        2. To determine role of serum amylase levels on day 1 to predict clinically relevant&#xD;
           pancreatic fistula&#xD;
&#xD;
        3. To determine risk factors for postoperative pancreatitis and postoperative pancreatic&#xD;
           fistula&#xD;
&#xD;
      Primaryendpoint:&#xD;
&#xD;
      Incidence of post operative pancreatitis and post operative pancreatic fistula.&#xD;
&#xD;
      Secondaryendpoints:&#xD;
&#xD;
        1. to identify the possible predictors of post operative pancreatitis.&#xD;
&#xD;
        2. to investigate the association between post operative pancreatitis and post operative&#xD;
           pancreatic fistula.&#xD;
&#xD;
      MATERIAL AND METHODS&#xD;
&#xD;
      Study centre:&#xD;
&#xD;
      Inpatient admissions in Department of gastroenterology, Asian institute of gastroenterology,&#xD;
      Hyderabad&#xD;
&#xD;
      Study population:&#xD;
&#xD;
      Patients who are supposed to undergo pancreaticoduodenectomy Study design: Prospective&#xD;
      observational study&#xD;
&#xD;
      Study period:&#xD;
&#xD;
      Study will be conducted till desired sample size achieved or March 2020 to march 2022&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY PROCEDURE:&#xD;
&#xD;
      Demographic, pathological and intraoperative data will be recorded in a prospectively&#xD;
      maintained database populated from a combination of electronic patient records, preoperative&#xD;
      imaging and anaesthetic charts. Preoperative clinical data included age, gender, body mass&#xD;
      index (BMI), and the results of serum biochemical investigations including serum bilirubin,&#xD;
      urea and amylase. The serum amylase measured throughout the study period is total amylase.&#xD;
      Preoperative computed tomography images will beanalyzed to calculate pancreatic duct diameter&#xD;
      at the line of transection of the pancreas anterior to the portal vein. Intraoperative data&#xD;
      included reconstruction technique, texture of the pancreatic remnant and estimated blood&#xD;
      loss. Blood loss data will be compiled from a combination of anaesthetic charts and&#xD;
      perioperative blood transfusion data. Specimens will be dichotomized according to whether&#xD;
      their pathology was associated with hard pancreatic parenchyma [pancreatic ductal&#xD;
      adenocarcinoma (PDAC) and chronic pancreatitis] or with soft or normal pancreatic parenchyma&#xD;
      (ampullary carcinoma, duodenal carcinoma, cholangiocarcinoma, neuroendocrine tumours and&#xD;
      other lesions). Outcome data included length of stay in a critical care environment [defined&#xD;
      as either an intensive care unit (ICU) or a surgical high-dependency unit (SHDU)] and length&#xD;
      of postoperative hospital stay. All postoperative complications will be prospectively&#xD;
      recorded and graded according to the International Study Group on Pancreatic Fistula (ISGPF)&#xD;
      and International Study Group of Pancreatic Surgery (ISGPS) classifications and the&#xD;
      Clavien-Dindo classification. Complications of ISGPS Grades B and C and Clavien-Dindo Grades&#xD;
      III-V are considered clinically significant. Mortality will be recorded at 30-day and 90-day&#xD;
      time-points.&#xD;
&#xD;
      Serum amylase will be systematically measured on POD1 and POD3 according to our institutional&#xD;
      policy. No additional radiological or laboratory studies are required for the diagnosis of&#xD;
      postoperative pancreatitis. No specific protocols for the treatment of POP will be followed&#xD;
      during the study period because none are available. Due to the absence of a widely accepted&#xD;
      definition, POP is defined according to Connor's definition1 as an elevation in serum&#xD;
      pancreatic amylase above the upper limit of normal on postoperative day (POD) 0 or 1. At our&#xD;
      institution, the upper limit of normal for serum pancreatic amylase is 100 U/L.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To estimate incidence of Post operative Pancreatitis and post operative pancreatic fistula among patients undergoing pancreaticoduodenectomies.</measure>
    <time_frame>10 days</time_frame>
    <description>After pancreaticoduodenectomy surgery, pancreatitis occurs it is a local inflammatory process occurring in the area of the pancreatic anastomosis after pancreas resection could induce increased systemic amylase concentration, Amylase normal range is 28--100, if it exceeds the upper normal limits it leads to post operative pancreatitis, pancreatic fistula is defined as persistent drainage of amylase rich fluid (3x &gt; than upper limit of normal serum amylase) for greater than 3 days.</description>
  </primary_outcome>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Pancreas Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Sample size : Required 35 subjects&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All patients (&gt;18 yrs) undergoing elective Whipple's PD in Asian institute of&#xD;
        gastroenterology, Hyderabad, Telangana.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  On table inoperable patients&#xD;
&#xD;
          -  Patients in cholangitis or bilirubin &gt; 15 mg/dl&#xD;
&#xD;
          -  Patients not giving consent for participation&#xD;
&#xD;
          -  Patients with acute inflammatory states (cholangitis, sepsis, trauma, acute on chronic&#xD;
             pancreatitis)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Pradeep Rebala, MBBS MS MCH</last_name>
    <role>Study Chair</role>
    <affiliation>Asian Institute of Gastroenterology, India</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr Shasheendra yanagandula, MBBS MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asian Institute of Gastroenterology, India</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dr Shasheendra Yanagandula, MBBS MS</last_name>
    <phone>9676050769</phone>
    <email>shasheendra8@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>RAJESH GOUD MARAGONI, M.PHARM, MBA</last_name>
    <phone>9705053550</phone>
    <email>rajeshgoud761@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asian Institute of Gastroenterology/AIG Hospitals</name>
      <address>
        <city>Hyderabad</city>
        <state>Telangana</state>
        <zip>500082</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Mohan Ramchandani, MBBS MD DM</last_name>
      <phone>04023378888</phone>
      <phone_ext>802</phone_ext>
      <email>ramchandanimohan@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Dr SHASHEENDRA YANAGANDULA, MBBS MS</last_name>
      <phone>9676050769</phone>
      <email>shasheendra8@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 12, 2020</study_first_submitted>
  <study_first_submitted_qc>August 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2020</study_first_posted>
  <last_update_submitted>August 14, 2020</last_update_submitted>
  <last_update_submitted_qc>August 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asian Institute of Gastroenterology, India</investigator_affiliation>
    <investigator_full_name>Mohan Ramchandani</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Pancreatic Fistula</mesh_term>
    <mesh_term>Pancreatic Diseases</mesh_term>
    <mesh_term>Fistula</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

